ATGC-110

botulinum toxin · ATGC Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ATGC-110, covering 2023-02-03 to 2023-02-03. Get the full timeline:

Most recent: Clinical Trial Update: Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines [Phase 3]

See pricing